Neogenomics Inc (NASDAQ:NEO) has a beta value of 1.39 and has seen 1.56 million shares traded in the last trading session. The company, currently valued at $1.30B, closed the last trade at $10.10 per share which meant it lost -$0.44 on the day or -4.17% during that session. The NEO stock price is -89.21% off its 52-week high price of $19.11 and 11.09% above the 52-week low of $8.98.
The consensus among analysts is that Neogenomics Inc (NEO) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.01.
Neogenomics Inc (NASDAQ:NEO) trade information
Sporting -4.17% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NEO stock price touched $10.10 or saw a rise of 5.25%. Year-to-date, Neogenomics Inc shares have moved -38.71%, while the 5-day performance has seen it change 1.10%. Over the past 30 days, the shares of Neogenomics Inc (NASDAQ:NEO) have changed -28.32%.
Wall Street analysts have a consensus price target for the stock at $18, which means that the shares’ value could jump 43.89% from current levels. The projected low price target is $18.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -78.22% off the targeted high while a plunge would see the stock gain -78.22% from current levels.
Neogenomics Inc (NEO) estimates and forecasts
The company’s shares have lost -35.71% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 11.72%.
12 analysts offering their estimates for the company have set an average revenue estimate of 171.68M for the current quarter. 12 have an estimated revenue figure of 183.18M for the next ending quarter. Year-ago sales stood 156.24M and 164.5M respectively for this quarter and the next, and analysts expect sales will grow by 9.88% for the current quarter and 11.72% for the next.
Earnings growth for 2025 is a modest 60.61% while over the next 5 years, the company’s earnings are expected to increase by 75.33%.
NEO Dividends
Neogenomics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Neogenomics Inc (NASDAQ:NEO)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 19.67 million shares worth more than $272.82 million. As of 2024-06-30, BLACKROCK INC. held 15.5612% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 14.12 million shares as of 2024-06-30. The firm’s total holdings are worth over $195.87 million and represent 11.1716% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 6.45% shares in the company for having 8.28 shares of worth $83.67 million while later fund manager owns 4.0 shares of worth $40.38 million as of Sep 30, 2024 , which makes it owner of about 3.11% of company’s outstanding stock.
